Blueshift Asset Management LLC Makes New $293,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Blueshift Asset Management LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, according to its most recent filing with the SEC. The firm purchased 1,067 shares of the biopharmaceutical company’s stock, valued at approximately $293,000.

Several other large investors have also recently made changes to their positions in the stock. Diversified Trust Co purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $1,210,000. Los Angeles Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares in the last quarter. Breakwater Capital Group purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter worth $249,000. Sanctuary Advisors LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $578,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in Alnylam Pharmaceuticals by 22.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock valued at $20,165,000 after buying an additional 13,422 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ALNY. HC Wainwright restated a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. Piper Sandler reiterated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. This represents a 8.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,370 shares of company stock worth $2,100,703 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.2 %

Shares of ALNY opened at $253.74 on Friday. The company’s 50-day moving average price is $271.93 and its 200 day moving average price is $240.19. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm has a market cap of $32.73 billion, a P/E ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The business’s revenue was down 33.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.15 EPS. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.